KPV vs Larazotide acetate
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Lys-Pro-Val, Alpha-MSH fragment
KPV is a tiny tripeptide, just three amino acids (lysine, proline, valine), that forms the tail end of the natural hormone alpha-MSH. It is studied almost entirely as an anti-inflammatory agent, particularly for gut and skin inflammation. There are no registered human clinical trials proving its benefits in people; the evidence base is cell-culture and animal studies, so anything you read about it treating disease is preliminary.
Also: Larazotide, AT-1001
Larazotide is an 8-amino-acid oral peptide (GGVLVQPG) designed to tighten the junctions between gut lining cells, aimed at celiac disease. For years it was the furthest-along celiac drug in development and it gets talked about online as a 'leaky gut' or zonulin blocker. The honest story is short: one phase 2b trial found a modest symptom benefit at the lowest dose only, the phase 3 trial was stopped in 2022 when it could not show a clear effect, and the sponsor 9 Meters Biopharma filed for Chapter 7 liquidation in July 2023. It is not approved anywhere.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
- Larazotide acetate has stronger research evidence (Human Trials) compared to KPV (Animal Studies).
Detailed Comparison
| Attribute | KPV | Larazotide acetate |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | What makes KPV interesting is how it gets into cells. Research suggests it hitches a ride on a nutrient transporter called PepT1, which is normally found in the small intestine but gets switched on in the colon during inflammation. Once inside the cell, KPV appears to interfere with NF-kB, a master switch that turns on inflammatory genes, which in lab studies reduces output of pro-inflammatory signals like TNF-alpha, IL-1beta, and IL-6. Unlike its parent hormone alpha-MSH, KPV does not seem to activate the classic melanocortin receptors, so its proposed action is described as largely receptor-independent. These mechanisms are supported by laboratory work but should be treated as a working model, not settled fact. | Larazotide is modeled on a fragment of Vibrio cholerae zonula occludens toxin, a region that overlaps with zonulin, the human protein that loosens tight junctions in the gut wall. The idea is that it blocks zonulin signaling and helps tight junctions reassemble, so gluten fragments have a harder time slipping between cells into the tissue underneath, where they trigger the immune reaction in celiac disease. It acts locally in the gut lumen and is not meant to be absorbed. That is a reasonable hypothesis with lab and animal support, but it is worth being clear: larazotide does not stop the immune response to gluten itself, and no human trial proved it protects the gut lining on biopsy. |
| Common Dosing | 200-500 mcg daily 1-2x daily | 0.5 mg three times daily before meals (trial dose) Three times daily, before meals |
| Administration | Subcutaneous injection or oral (capsules) | Oral capsule taken before meals, alongside a gluten-free diet (not instead of it) |
| Typical Duration | 4-8 weeks typical | 12 weeks of treatment in the phase 2b trial |
| Best Time to Take | Morning or as directed | About 15 minutes before each main meal (trial protocol) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The honest picture: KPV's reputation rests on animal and in vitro research, not human trials. A frequently cited study in Gastroenterology (Dalmasso and colleagues, 2008) showed PepT1-mediated uptake of KPV reduced intestinal inflammation, and oral KPV lessened chemically induced colitis (DSS and TNBS models) in mice while lowering pro-inflammatory cytokines. A later 2016 study in PMC reported KPV also reduced tumor number in a mouse model of colitis-associated cancer in a PepT1-dependent way. These are genuinely interesting, reproducible animal findings. But there are no published randomized controlled trials in humans for inflammatory bowel disease, eczema, or any of the conditions it is marketed for. Claims that it treats Crohn's, leaky gut, or mast cell activation in people are extrapolations from rodent data, not proven outcomes. | The key human study is a phase 2b trial published in Gastroenterology in 2015 (Leffler and colleagues, NCT01396213). It randomized 342 adults with celiac disease who still had symptoms on a gluten-free diet to 0.5 mg, 1 mg, or 2 mg three times daily or placebo for 12 weeks. Only 0.5 mg met the primary endpoint (symptom score 2.59 vs 2.88), with 26% fewer symptomatic days. The 1 mg and 2 mg doses did nothing measurable, an odd inverse dose response the authors could not explain (peptide aggregation was one guess), and most secondary endpoints missed. Safety looked similar to placebo. The phase 3 CedLara trial (NCT03569007) then tested the same 0.5 mg dose, but in June 2022 an interim analysis showed the number of patients needed to separate drug from placebo was too large to continue, and the trial was terminated. 9 Meters later pointed larazotide at COVID-related conditions such as MIS-C, then filed Chapter 7 in July 2023. We found no active development after that. Bottom line: one positive-ish phase 2b, one stopped phase 3, no approval. |
Frequently Asked Questions: KPV vs Larazotide acetate
What is the difference between KPV and Larazotide acetate?
KPV is a immune peptide that kpv is a tiny tripeptide, just three amino acids (lysine, proline, valine), that forms the tail end of the natural hormone alpha-msh. it is studied almost entirely as an anti-inflammatory agent, particularly for gut and skin inflammation. there are no registered human clinical trials proving its benefits in people; the evidence base is cell-culture and animal studies, so anything you read about it treating disease is preliminary. Larazotide acetate is a immune peptide that larazotide is an 8-amino-acid oral peptide (ggvlvqpg) designed to tighten the junctions between gut lining cells, aimed at celiac disease. for years it was the furthest-along celiac drug in development and it gets talked about online as a 'leaky gut' or zonulin blocker. the honest story is short: one phase 2b trial found a modest symptom benefit at the lowest dose only, the phase 3 trial was stopped in 2022 when it could not show a clear effect, and the sponsor 9 meters biopharma filed for chapter 7 liquidation in july 2023. it is not approved anywhere. The main differences lie in their mechanisms of action and clinical applications.
Which is better, KPV or Larazotide acetate?
Neither is universally "better" - the choice depends on your specific goals. KPV is typically used for immune purposes, while Larazotide acetate is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can KPV and Larazotide acetate be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using KPV and Larazotide acetate together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.